Anticoagulant therapy likely increases risk of bleeding in Gynura segetum-induced hepatic sinus obstruction syndrome.
Medicine (Baltimore)
; 103(6): e35914, 2024 Feb 09.
Article
em En
| MEDLINE
| ID: mdl-38335400
ABSTRACT
This study aimed to analyze the clinical characteristics of Gynura segetum (Tusanqi)-induced hepatic sinusoidal obstruction syndrome (HSOS) and the benefits and risks of anticoagulant therapy for Tusanqi-induced HSOS. This was a retrospective analysis of 49 patients with Tusanqi-induced HSOS who were treated with anticoagulation or standard therapy between July 2006 and December 2022. Clinical manifestations included abdominal pain (nâ
=â
47) and peritoneal or pleural effusion (nâ
=â
46); 2 patients died. Nineteen patients requested standard medical treatment, while 30 were treated with anticoagulants. HSOS resolved within 6 months in 22 patients but did not resolve in 27 patients. The resolution rate was higher in the anticoagulant than standard treatment group (Pâ
=â
.037). Logistic regression analysis revealed that a history of chronic liver disease or treatment increased the risk of poor outcomes. Bleeding complications occurred in 6 patients in the anticoagulant treatment group. Early diagnosis and anticoagulant treatment are beneficial for rapid recovery after Tusanqi-induced HSOS. However, anticoagulant treatment is associated with the risk of multisite bleeding.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hepatopatia Veno-Oclusiva
/
Medicamentos de Ervas Chinesas
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article